Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Profit After Tax (2020 - 2025)

Historic Profit After Tax for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to -$35.7 million.

  • TScan Therapeutics' Profit After Tax fell 1948.34% to -$35.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$142.6 million, marking a year-over-year decrease of 2810.89%. This contributed to the annual value of -$127.5 million for FY2024, which is 4290.84% down from last year.
  • As of Q3 2025, TScan Therapeutics' Profit After Tax stood at -$35.7 million, which was down 1948.34% from -$37.0 million recorded in Q2 2025.
  • In the past 5 years, TScan Therapeutics' Profit After Tax ranged from a high of -$7.9 million in Q1 2021 and a low of -$37.0 million during Q2 2025
  • Its 5-year average for Profit After Tax is -$23.1 million, with a median of -$22.6 million in 2023.
  • Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 12090.66% in 2021, then plummeted by 256.33% in 2022.
  • Quarter analysis of 5 years shows TScan Therapeutics' Profit After Tax stood at -$14.2 million in 2021, then tumbled by 31.84% to -$18.7 million in 2022, then dropped by 4.76% to -$19.6 million in 2023, then tumbled by 82.53% to -$35.8 million in 2024, then rose by 0.25% to -$35.7 million in 2025.
  • Its Profit After Tax was -$35.7 million in Q3 2025, compared to -$37.0 million in Q2 2025 and -$34.1 million in Q1 2025.